U.S. stock futures edge higher ahead of Powell’s Jackson Hole speech
Artivion, Inc. NASDAQ:AORT Chief Commercial Officer John E. Davis sold 10,802 shares of common stock on August 12, 2025, for a total of $471,755. The price per share ranged from $43.470 to $43.835, with the transaction occurring near the stock’s 52-week high of $43.97. According to InvestingPro data, Artivion shares have delivered an impressive 78% return over the past year.
Davis also exercised options to acquire 10,802 shares of Artivion common stock at a price of $26.24, for a total value of $283,444. Following these transactions, Davis directly owns 208,778 shares of Artivion, a medical device company currently valued at $2.04 billion. InvestingPro analysis indicates the stock is trading at premium valuations, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US equities.
In other recent news, Artivion Inc. reported strong second-quarter earnings, with revenue reaching $113 million. This figure surpassed consensus expectations of approximately $108 million and demonstrated a 14% year-over-year growth. The company’s performance prompted several analysts to adjust their outlooks. Stifel raised its price target for Artivion to $40, maintaining a Buy rating due to the robust launch of the AMDS stent and stent-graft product. Similarly, Needham increased its price target to $45, citing growth acceleration, while Canaccord Genuity also raised its target to $41, highlighting the company’s adjusted EBITDA of $24.8 million, which exceeded estimates. Oppenheimer initially raised its price target to $40, maintaining an Outperform rating, but later adjusted it from $42 while still acknowledging the company’s strong performance. Overall, Artivion’s recent earnings report has led to positive revisions in analyst price targets, reflecting optimism about the company’s future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.